Project title
Pre-clinical drug development of TR4 for the treatment of human carcinomas
Funding Program
EUROSTARS
Funding code
Trojandrug
TROJANDRUG (8520)
Start date
October 3, 2013
Expected Completion
2015-10-02
Description
The TROJANDRUG project aims to carry out the first pre-clinical drug development using innovative capabilities and expertise previously unavailable in Cyprus. The proposed consortium has been assembled to provide the proper pre-clinical setting that will enable the TR4 cancer drug molecule developed by Trojantec, to cross the barrier from pre-clinical phase and into the clinical trial phase, the first of its kind in Cyprus. The project consortium recognizes the need for initiatives that foster synergies between industry and academia and among EU countries, and considers the role and input of each P as integral to the successful execution of the project. The project Ps further acknowledge that without critical EU funding provided through national funding schemes as well as from the collaborating Ps, this innovate proposal will not be successful as Cyprus is only just beginning to develop such novel pharmaceutical core capabilities._x000D__x000D_The cancer inhibiting potential of the TR4 fusion protein is based on increasing available evidence, which suggests that the same molecular pathways regulating the self-renewal of stem cells are also being employed in cancer progression.